Self-Assessment: Add-on Therapy for SMA | Navigating Through the Available Therapies for Duchenne: How Do You Choose?

From 2024 Annual Meeting session content.

Course Description

Add-On Therapy for SMA
Explore the effect of myostatin inhibitors on patients with Spinal Muscular Atrophy; examine the state of various antisense oligonucleotide therapies; and survey other small molecule therapies in early studies as well as “add-on” intrathecal gene therapy for older patients with SMA.

Meeta Cardon, MD | Jenna Klotz, MD | Ashley N. Stanley-Copeland, MD

Navigating Through the Available Therapies for Duchenne: How Do You Choose?
Review the current FDA approved therapies for DMD and discuss the benefits and limitations of each.; recognize the role of each in the general landscape of treatment.; and create a framework for thinking through how to apply these therapies to real world patients.

Craig M. Zaidman, MD | Nancy L. Kuntz, MD

Objectives:
1. Explore the effect of myostatin inhibitors on patients with Spinal Muscular Atrophy; examine the state of various antisense oligonucleotide therapies.
2. Review the current FDA approved therapies for DMD and discuss the benefits and limitations of each.; recognize the role of each in the general landscape of treatment.; and create a framework for thinking through how to apply these therapies to real world patients.

To claim self-assessment (SA) credit, you must watch the session recordings and answer a post-test. You must get above a 70% on the post-test survey to claim credit.

The American Board of Psychiatry and Neurology (ABPN) and the American Board of Physical Medicine and Rehabilitation (ABPMR) have reviewed and approved this product as part of a comprehensive lifelong learning program, which is mandated by the American Board of Medical Specialties (ABMS) as a necessary component of maintenance of certification (MOC).

ACCREDITATION STATEMENT : The AANEM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION :
The AANEM designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits ^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE INFORMATION:
Dr. Meeta Cardon is a consultant for Life Sciences Consulting Dr. Ashley Stanley-Copeland receives consulting fees for Novartis and Catalyst. Dr. Craig Zaidman is a consultant for Biogen. Dr. Nancy Kuntz is on the advisory board for Astellas, argenx, Catalyst, Entrada, Genentech, Novartis and Sarepta, is an Exchange Expert On-Demand Program Speaker for Sarepta, speaker for Genentech, Sarepta, Solid Biosciences and receives research funding from Astellas, argenx, Biogen, Catalyst, Genentech, Novartis and Sarept. The full disclosure guide for all session planners can be found here. All conflicts of interest have been resolved in accordance with ACCME Standards for commercial support and ineligible companies.

Summary


Availability:	On-Demand
	Expires on Oct 14, 2027


Cost:	Member: $50.00 Non-Member: $75.00


Credit Offered:	3 SA CME Credits 3 CEU Credits